Collegium Pharmaceutical Inc (COLL): Price-to-Revenue Ratio

Collegium Pharmaceutical (COLL) is limited to the US market, which eliminates sanction risks, yet the company faces regulatory pressure and opioid-related lawsuits. The business valuation based on P/S demonstrates market value dynamics relative to sales, while 0.90 records a new level mark. The company generates revenue from the sale of patented abuse-deterrent pain management medications.

To objectively value Collegium Pharmaceutical (COLL), one must compare the business's market value with its actual turnover. By analyzing the price-to-sales ratio, an investor determines the cost of one dollar of revenue, which is critical for a company subject to strict FDA and DEA production quotas for opioids. The decline of this metric on the chart confirms the undervaluation of the protected pain management ecosystem and increases the reliability of the investment.